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Abstract
System L is a major nutrient transport system responsible for the Na + -independent transport of large neutral amino acids including
several essential amino acids. In malignant tumors, a system L transporter L-type amino acid transporter 1 (LAT1) is up-regulated to support
tumor cell growth. LAT1 is also essential for the permeation of amino acids and amino acid-related drugs through the blood–brain barrier. To
search for in vitro assay systems to examine the interaction of chemical compounds with LAT1, we have investigated the expression of
system L transporters and the properties of [14C]L-leucine transport in T24 human bladder carcinoma cells. Northern blot, real-time
quantitative PCR and immunofluorescence analyses have reveled that T24 cells express LAT1 in the plasma membrane together with its
associating protein 4F2hc, whereas T24 cells do not express the other system L isoform LAT2. The uptake of [14C]L-leucine by T24 cells is
Na + -independent and almost completely inhibited by system L selective inhibitor BCH. The profiles of the inhibition of [14C]L-leucine
uptake by amino acids and amino acid-related compounds in T24 cells are comparable with those for the LAT1 expressed in Xenopus
oocytes. The majority of [14C]L-leucine uptake is, therefore, mediated by LAT1 in T24 cells. Consistent with LAT1 in Xenopus oocytes, the
efflux of preloaded [14C]L-leucine is induced by extracellularly applied substrates of LAT1 in T24 cells. This efflux measurement has been
proven to be more sensitive than that in Xenopus oocytes, because triiodothyronine, thyroxine and melphalan were able to induce the efflux
of preloaded [14C]L-leucine in T24 cells, which was not detected for Xenopus oocyte expression system. T24 cell is, therefore, proposed to be
an excellent tool to examine the interaction of chemical compounds with LAT1.
D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
System L is a plasma membrane amino acid transport
system which mediates Na + -independent transport of
large neutral amino acids [1,2]. It is a major route
through which living cells including tumor cells take up
branched or aromatic amino acids. In addition, system L
is present in the basolateral membrane of epithelial cells
and plays important roles in the absorption of amino
acids through the epithelial cells of small intestine and
renal proximal tubules [1]. System L is also pivotal in
the permeation of amino acids through the blood–tissue
barriers such as blood–brain barrier and placenta barrier
[1]. A remarkable feature of system L is its broad
substrate selectivity [3]. Because of this property, system
L is regarded as a drug transporter which transports not
only naturally occurring amino acids but also amino acid-
related drugs such as L-dopa, melphalan, thyroid hor-
mones and gabapentin [1,4–8].
By expression cloning, we isolated the first isoform of
system L amino acid transporter LAT1 (L-type amino acid
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transporter 1) from C6 rat glioma cells [9]. LAT1 is a 12-
membrane-spanning protein which mediates a Na + -inde-
pendent amino acid exchange. It prefers large neutral amino
acids such as leucine, isoleucine, valine, phenylalanine,
tyrosine, tryptophan, methionine and histidine for its sub-
strates [9–11]. We and other researchers further demonstra-
ted that a single-membrane-spanning protein, the heavy
chain of 4F2 antigen (4F2hc), is essential for the functional
expression of LAT1. LAT1 and 4F2hc form a heterodimeric
complex via a disulfide bond [9,10,12–15]. Although the
expression of 4F2hc is ubiquitous, the expression of LAT1 is
restricted to certain tissues such as brain, placenta and testis
[9,10]. LAT1 is highly expressed in cultured cells and
malignant tumors, presumably to support their continuous
growth [9,10,16,17]. Recently, it was demonstrated that
LAT1 and 4F2hc proteins are present in the luminal and
abluminal membranes of brain capillary endothelial cells,
components of the blood–brain barrier [18–21]. Following
the identification of LAT1, transporters structurally related to
LAT1 have been found to be associated with 4F2hc or another
single-membrane-spanning subunit rBAT (related to b0, +
amino acid transporter) [3,22]. These transporters include
systems asc, y + L, xc
 and b0, + as well as the second system
L isoform, LAT2 [3,22]. LAT2 is more ubiquitously ex-
pressed than LAT1 and transports not only large neutral
amino acids but also small neutral amino acids [23–25].
Based on what is mentioned above, it is proposed that the
manipulation of system L activity, in particular that of
LAT1, would have therapeutic implications. The inhibition
of LAT1 activity in tumor cells could be effective in the
inhibition of tumor cell growth by depriving tumor cells of
essential amino acids [3]. The availability of in vitro assay
systems for the interaction with LAT1 would facilitate the
development of such drugs. It would, in addition, be
beneficial to design drugs with efficient permeation through
the blood–brain barrier utilizing LAT1 as a permeation
path. The functional properties of LAT1 have been studied
formerly by injecting LAT1 cRNA into Xenopus oocytes or
by transiently transfecting LAT1 cDNA to cultured mam-
malian cells, which is not well-suited for the efficient
screening of chemical compounds [9–12,15,26]. Therefore,
we have characterized the system L-mediated amino acid
transport in T24 human bladder carcinoma cells, which was
previously shown to express high levels of messages for
LAT1 and 4F2hc [10]. We report here that L-leucine uptake
by T24 cells is almost exclusively mediated by LAT1, so
that T24 cells would be an excellent tool to examine the
interaction of chemical compounds with LAT1.
2. Materials and methods
2.1. Materials
[14C]L-leucine was purchased from Perkin Elmer Life
Sciences Inc. (Boston, MA). Gabapentin and droxidopa were
kindly provided by Parke-Davis Pharmaceutical Research
(Ann Arbor, MI) and Sumitomo Pharmaceutical Co. Ltd.
(Osaka, Japan), respectively. Mouse anti-human CD98
(4F2hc) monoclonal antibody was purchased from Ancell
(Bayport, MN). Affinity-purified rabbit anti-LAT1 polyclo-
nal antibody was supplied by Kumamoto Immunochemical
Laboratory, Transgenic Inc. (Kumamoto, Japan). Cy3-con-
jugated goat anti-rabbit IgG and FITC-conjugated rabbit anti-
mouse IgG were obtained from Jackson ImmunoResearch
Laboratories Inc. (West Grove, PA) and DAKO (Glostrup,
Denmark), respectively. Other chemicals were purchased
from Sigma (St. Louis, MO). T24 human bladder carcinoma
cells were provided by the Health Science Research Resour-
ces Bank, Japan Health Sciences Foundation (Osaka, Japan).
2.2. Northern blot analysis
RNA was prepared form T24 cells maintained in the
growth medium (minimum essential medium supplemented
with 10% fetal bovine serum) at 37 jC by the guanidinium
isothiocyanate method using cesium–trifluoroacetic acid
(Amersham Pharmacia Biotech) in accordance with the
manufacturer’s instruction. Poly(A) + RNA was selected by
oligo(dT) cellulose chromatography (Amersham Pharmacia
Biotech) [27]. Human kidney poly(A) + RNA was pur-
chased from Clontech. Poly(A) + RNA (3 Ag/lane) was
separated on a 1% agarose gel in the presence of 2.2 M
formaldehyde and was blotted onto a nitrocellulose filter
(Schleicher and Schuell) as described elsewhere [27]. The
SmaI fragment of human LAT1 cDNA corresponding to
649–1128 bp of human LAT1 nucleotide sequence (Gen-
Bank/EMBL/DDBJ accession no. AB018009), the PstI
fragment of human 4F2hc cDNA corresponding to 106–
645 bp of human 4F2hc nucleotide sequence (GenBank/
EMBL/DDBJ accession no. AB018010) and the BstEII
fragment of human LAT2 cDNA corresponding to 1001–
1847 bp of human LAT2 nucleotide sequence (GenBank/
EMBL/DDBJ accession no. AB037669) were labeled with
[32P]dCTP using a T7Quick prime kit (Pharmacia). Hybrid-
ization was performed for 20 h at 42 jC as described
elsewhere [27]. The filters were washed in 0.1 SSC/
0.1% SDS at 65 jC [27].
2.3. Real-time quantitative RT-PCR
For real-time quantitative RT-PCR analysis, total RNA
was prepared from T24 cells using an RNA preparation kit
(Isogen, Nippon-Gene, Japan) following the manufacturer’s
instructions. The total RNA was treated with DNase I
(Boehringer Mannheim; 1 unit per 10 mg of RNA) at 25
jC for 20 min. First-strand cDNA was produced using
SuperScript First-Strand Synthesis System for RT-PCR (Life
Technologies) with an oligo dT primer [28]. Five micro-
grams of total RNA were used for a reverse transcription
reaction (20 Al). For the real-time quantitative PCR, 1 Al out
of the 20 Al reverse transcription reaction mixture was used.
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Standard first-strand cDNAs for LAT1, LAT2 and 4F2hc
were synthesized from each cRNA. LAT1 cRNA was
obtained by in vitro transcription using T3 RNA polymerase
from the LAT1 cDNA (GenBank/EMBL/DDBJ accession
no. AB018009) in pBluescript II SK  (Stratagene) linearized
with XhoI [29]. LAT2 and 4F2hc cRNAs were also obtained
by in vitro transcription using SP6 RNA polymerase for
LAT2 cDNA (GenBank/EMBL/DDBJ accession no.
AB037669) in pSPORT 1 (Life Technologies) linearized
with RsrII and T7 RNA polymerase for 4F2hc cDNA
(GenBank/EMBL/DDBJ accession no. AB018010) in pBlue-
script II SK linearized with BamHI, respectively [29]. The
first-strand cDNAs were synthesized as described above
using cRNAs for LAT1, LAT2 and 4F2hc as templates [28].
The 7700 Sequence Detector System (Perkin Elmer/
Applied Biosystems) was used for real-time quantitative
RT-PCR analyses [30]. The RT-PCR reaction mixture (50
Al) included reverse transcription products corresponding
to 250 ng of total RNA or standard first-strand cDNAs
corresponding to 25 fg–25 ng of cRNA, 25 Al of
Taqman Universal PCR Master Mix (Perkin Elmer/Applied
Biosystems), 0.5 Al of forward and reverse primer (10 AM)
and 1 Al of corresponding Taqman probe (5 AM) [30]. RT-
PCR cycle parameters were 50 jC for 2 min, 95 jC for 10
min, followed by 40 cycles at 95 jC for 15 s and 60 jC
for 1 min. The primers and the probes were designed using
Primer Express software (Perkin Elmer/Applied Biosys-
tems) and synthesized by Perkin Elmer/Applied Biosys-
tems. For LAT1, the forward and reverse primers were 5V-
GAT CCT GCT GGG CTT CGT-3Vand 5V-AGT TTG GTG
CCT TCA AAT GAG AA-3V, respectively, and the Taqman
probe was 6 FAM-AGA TCG GGA AGG GTG ATG TGT
CCA ATC-TAMRA. For 4F2hc, the forward and reverse
primers were 5V-CTC AGG CAA GGC TCC TGA CT-3V
and 5V-GGC AGG GTG AAG AGC ATC A-3V, respectively,
and the Taqman probe was 6 FAM-TGC CGG CTC AAC
TTC TTC GAC TCT AC-TAMRA. For LAT2, the forward
and reverse primers were 5V-AAT GCATTT GAG AAT TTC
CAG GA-3Vand 5V-GAG CCC TGA AGG AAA GCC A-3V,
respectively, and the Taqman probe was 6 FAM-CCT GAC
ATC GGC CTC GTC GCA-TAMRA. The concentration of
reverse and forward primers used was 900 nM for each. The
concentration of probe was 250 nM.
2.4. Immunofluorescence of T24 cells
T24 cells on the culture plates were fixed with 4%
paraformaldehyde for 1 h. The cells were collected by
scraping and centrifugation at 1000 rpm for 5 min. The cells
were then resuspended in warmed 2% agar solution, centri-
fuged at 3000 rpm for 5 min and cooled for 30 min at 4 jC.
The cell pellets in solid agar were again fixed with 4%
paraformaldehyde for 3 h, embedded in paraffin wax and
processed for paraffin sectioning.
Sections (3 Am) were dewaxed, rehydrated and incuba-
ted with affinity-purified anti-LAT1 polyclonal antibody
(1:100) overnight at 4 jC and then with mouse anti-human
CD98 (4F2hc) monoclonal antibody (Ancell; diluted 1:100)
for 2 h at room temperature [18]. Thereafter, they were
treated with Cy3-conjugated goat anti-rabbit IgG (Jackson
ImmunoResearch Laboratories) for 1 h, and then, FITC-
conjugated rabbit anti-mouse IgG (DAKO) for 1 h at room
temperature. Images were acquired using a Carl Zeiss laser-
scanning confocal microscope LSM 510 equipped with a
X63 immersion objective [18]. An He–Ne laser beam was
used for excitation at 543 nm for Cy3 visualization. Emis-
sion from Cy3 was detected via an LP585 filter. For FITC
visualization, an argon laser beam was used for excitation at
488 nm. Emission from FITC was detected via a LP505
filter.
2.5. Uptake measurements in T24 cells
T24 cells were maintained in the growth medium (mini-
mum essential medium supplemented with 10% fetal bovine
serum) at 37 jC in 5% CO2. The cells were collected and
seeded on 24-well plates (1105 cells/well) in the fresh
growth medium. The uptake measurements were performed
at 48 h after seeding.
After the removal of the growth medium, the cells were
washed three times with the standard uptake solution (125
mM NaCl, 4.8 mM KCl, 1.3 mM CaCl2, 1.2 mM MgSO4,
25 mM HEPES, 1.2 mM KH2PO4, 5.6 mM glucose, pH 7.4)
or Na + -free uptake solution (125 mM choline-Cl, 4.8 mM
KCl, 1.3 mM CaCl2, 1.2 mM MgSO4, 25 mM HEPES, 1.2
mM KH2PO4, 5.6 mM glucose, pH 7.4), and preincubated
for 10 min at 37 jC. Then, the medium was replaced by the
uptake solution containing [14C]L-leucine. The uptake was
terminated by removing the uptake solution followed by
washing three times with ice-cold uptake solution [31,32].
Then, cells were solubilized with 0.1 N NaOH and radio-
activity was counted by liquid scintillation spectrometry.
The values are expressed as pmol/mg protein/min. For the
measurement of the uptake of [14C]L-leucine, four to six
wells of T24 cells were used for each data point. To confirm
the reproducibility of the results, three or four separate
experiments were performed for each measurement. Results
from the representative experiments are shown in the
figures.
For the inhibition experiments, the uptake of 20 AM
[14C]L-leucine was measured in the presence or absence of 2
mM nonlabeled test compounds, unless otherwise indicated
[9–11]. For triiodothyronine, thyroxine and melphalan, the
effects of 100 AM nonradiolabeled compounds were exam-
ined on the uptake of 1 AM [14C]L-leucine in the uptake
solution containing a final concentration of 0.1% DMSO
[10,11].
Km and Vmax values were determined using Eadie–
Hofstee plots based on the [14C]L-leucine uptake meas-
ured for 1 min at 1, 3, 10, 20, 30, 100, 300 and 1000
AM. To determine the Ki values, the uptake rates of
[14C]L-leucine were measured for 1 min at varied con-
D.K. Kim et al. / Biochimica et Biophysica Acta 1565 (2002) 112–122114
centrations with or without addition of inhibitors. The Ki
values were determined by double-reciprocal plot analysis
in which 1/uptake rate of [14C]L-leucine was plotted
against 1/L-leucine concentration. The Ki values were
calculated from the following equation when competitive
inhibition was observed: Ki = concentration of inhibitor/
((Km of L-leucine with inhibitor/Km of L-leucine without
inhibitor) 1) [11,33].
2.6. Efflux measurements
T24 cells were incubated for 10 min in the uptake
solution containing 1 AM [14C]L-leucine (2 ACi/ml) to
load the T24 cells with [14C]L-leucine [9–11]. The T24
cells were then washed three times with uptake solution
and incubated in 500 Al uptake solution with or without
addition of test compounds. After incubation, 500 Al of
incubation medium was removed from the well. Then,
cells were solubilized with 0.1 N NaOH and the radio-
activity was counted by liquid scintillation spectrometry.
The radioactivity in the medium and the remaining
radioactivity in the T24 cells were measured. The values
were expressed as % radioactivity (radioactivity of
medium or T24 cells/(radioactivity of medium + radioac-
tivity of T24 cells)) [9,11]. Km values of the [
14C]L-
leucine efflux induced by extracellularly applied L-leucine
was determined using the Eadie–Hofstee plot based on
the [14C]L-leucine efflux measured for 1 min at 1, 10, 30,
100, 300, 1000 and 3000 AM of extracellularly applied L-
leucine [11].
Fig. 1. Expressions of LAT1 and 4F2hc in T24 cells. Northern blots of
poly(A) + RNA isolated from T24 cells (T24) were compared with those of
human kidney poly(A) + RNA (Kidney). High stringency Northern blot
analysis of poly(A) + RNA (3 Ag) from T24 cells and human kidney were
performed using 32P-labeled LAT1, LAT2 and 4F2hc cDNAs as probes. In
T24 cells, strong hybridization was detected for LAT1 (4.8 kb) and 4F2hc
(2.2 kb), but not for LAT2. Human kidney poly(A) + RNA was used as a
positive control for LAT2 (4.4 kb).
Fig. 2. Immunodetection of LAT1 and 4F2hc in T24 cells by confocal laser-
scanning microscopy. Confocal immunofluorescence microscopic analysis
was performed on T24 cells as described in Materials and methods. Both
LAT1 immunoreactivity (red; A) and 4F2hc immunoreactivity (green; B)
were detected on the plasma membrane of T24 cells. LAT1 immunostaining
(red) and 4F2hc immunostaining (green) were merged and shown in (C),
indicating the coexistence of LAT1 and 4F2hc in the plasma membrane of
T24 cells.
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2.7. Data analysis
All experiments were performed in triplicate. Results are
presented as meanF S.E. Statistical significance was ana-
lyzed by using Student’s t-test for two groups and one-way
analysis of variance for multi-group comparisons. P < 0.05
is considered statistically significant.
3. Results
3.1. Detection of LAT1 as the system L transporter in T24
cells
In Northern blot analyses, mRNAs for LAT1 and its
associating protein 4F2hc were detected in T24 cells (Fig.
1). The LAT2 message was not detected in T24 cells,
whereas human kidney poly(A) + RNA used as a positive
control for LAT2 [23,24] exhibited high levels of expression
of LAT2 as well as 4F2hc (Fig. 1). Consistent with the
previous report, LAT1 message was not detected in human
kidney [10].
The presence of LAT1 and 4F2hc in T24 cells was
further examined by real-time quantitative RT-PCR. In the
real-time quantitative RT-PCR, LAT1 and 4F2hc were
detected in T24 cells (data not shown). The amount of
LAT1 was found to be f 1.5-fold higher than that of 4F2hc
in T24 cells (10.44F 0.97 10 18 mol/Ag total RNA vs.
6.15F 0.45 10 18 mol/Ag total RNA). Consistent with the
result form the Northern blot analysis (Fig. 1), LAT2 was
Fig. 3. [14C]L-Leucine uptake by T24 cells. (A) Ion dependence of [14C]L-
leucine transport. [14C]L-Leucine (20 AM) uptake measured in the standard
uptake solution (Na) was compared with that measured in the Na + -free
uptake solution (Choline). The [14C]L-leucine transport measurements were
performed at 37 jC and on ice. (B) Inhibition of [14C]L-leucine transport by
BCH, a specific inhibitor of system L. The [14C]L-leucine (20 AM) uptake
was measured in the presence (BCH) or absence ( ) of 2 mM BCH.
Fig. 4. Time course and concentration dependence of [14C]L-leucine uptake
by T24 cells. (A) The dependence of [14C]L-leucine uptake on the
incubation time. T24 cells were incubated in the Na + -free uptake solution
containing 20 AM [14C]L-leucine for 0.5–30 min. (B) Concentration
dependence of [14C]L-leucine uptake in T24 cells. The uptake of [14C]L-
leucine by T24 cells was measured for 1 min and plotted against L-leucine
concentration. L-Leucine uptake was saturable and fit to the Michaelis–
Menten curve (Km= 100.5 AM; Vmax = 23,878 pmol/mg protein/min). The
inset shows an Eadie–Hofstee plot of L-leucine uptake that was used to
determine the kinetic parameters.
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not detected in T24 cells in real-time quantitative RT-PCR
(data not shown).
In the confocal immunofluorescence microscopic analy-
ses, LAT1 and 4F2hc proteins were detected in T24 cells
(Fig. 2A and B). They were found to be mainly colocalized
in the plasma membrane (Fig. 2C). The results from North-
ern blot analysis, real-time quantitative RT-PCR and con-
focal immunofluorescence microscopic analysis indicate
that LAT1 but not LAT2 is present together with 4F2hc in
the plasma membrane of T24 cells.
3.2. The properties of [14C]L-leucine uptake by T24 cells
The properties of [14C]L-leucine transport were examined
in T24 cells. As shown in Fig. 3A, the level of [14C]L-
leucine uptake (20 AM) by T24 cells measured in the
standard uptake solution was not altered by replacing NaCl
of the uptake solution with choline-Cl, indicating that
L-leucine uptake by T24 cells is largely Na + -independent.
In the subsequent experiments, the transport measurements
were performed under Na + -free conditions. As shown in
Fig. 3B, the uptake of [14C]L-leucine (20 AM) was almost
completely inhibited by 2 mM BCH, indicating that system
L is responsible for the [14C]L-leucine uptake by T24 cells.
The [14C]L-leucine uptake was not detected when the
uptake measurements were performed on ice, confirming
that the [14C]L-leucine uptake by T24 cells was due to the
transporter-mediated transport (Fig. 3A).
To determine the time course of [14C]L-leucine uptake by
T24 cells, the level of uptake was measured for 0.5–30 min
(Fig. 4A). Uptake of [14C]L-leucine (20 AM) was time-
dependent and exhibited a linear dependence on the incu-
bation time up to 1 min (Fig. 4A); all subsequent uptake
measurements were conducted for 1 min and the values are
expressed as pmol/mg protein/min. As shown in Fig. 4B,
[14C]L-leucine uptake was saturable and followed Michae-
lis–Menten kinetics with a Km values of 100.5F 11.7 AM
Fig. 5. Inhibition of [14C]L-leucine uptake by amino acids in T24 cells. The
[14C]L-leucine uptake (20 AM) was measured in the presence of 2 mM
nonradiolabeled indicated L-amino acids and system L specific inhibitor
BCH (A) and D-amino acids (D-isomers) (B).
Fig. 6. The inhibitory effect of BCH on [14C]L-leucine uptake in T24 cells.
(A) The concentration-dependent inhibition of [14C]L-leucine uptake by
BCH. The [14C]L-leucine uptake (1 AM) was measured for 1 min in the
Na + -free uptake solution in the presence of varied concentrations of BCH
and expressed as a percentage of control L-leucine uptake in the absence of
BCH. (B) Double reciprocal plot analyses of the inhibitory effect of BCH
on [14C]L-leucine uptake. The [14C]L-leucine uptake (1, 3, 10, 30, 100, 300
and 1000 AM) was measured in the Na + -free uptake solution in the
presence (50 AM, filled square; 100 AM, filled triangle) or absence (filled
circle) of BCH.
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(meanF S.E. of three separate experiments) for [14C]L-
leucine uptake.
3.3. Inhibition of [14C]L-leucine uptake by amino acids and
amino acid-related compounds
In order to examine which compounds interact with L-
leucine uptake by T24 cells, the [14C]L-leucine uptake (20
AM) was measured in the presence of 2 mM nonlabeled
amino acids and amino acid-related compounds in the Na + -
free uptake solution. The [14C]L-leucine uptake was highly
inhibited by L-isomers of cysteine, methionine, isoleucine,
valine, phenylalanine, tyrosine, tryptophan, histidine and
BCH (Fig. 5A). Threonine, asparagine and glutamine and
some other L-amino acids exhibited weaker inhibitory
effects on [14C]L-leucine transport (Fig. 5A).
As shown in Fig. 5B, [14C]L-leucine uptake was mark-
edly inhibited by D-isomers of methionine, leucine, isoleu-
cine, phenylalanine and tyrosine, and less strongly by D-
cysteine, D-asparagine and D-histidine, which is, in principle,
consistent with the properties of LAT1 expressed in the
Xenopus oocytes [9].
BCH (1–1000 AM) inhibited [14C]L-leucine uptake (1
AM) in a concentration-dependent manner (Fig. 6A) with a
IC50 value of 131.5F 11.4 AM (meanF S.E. of four sepa-
rate experiments) (Fig. 6A). The inhibition of [14C]L-leucine
uptake by BCH was shown to be competitive in a double
reciprocal plot analysis with a Ki value of 156.2F 7.9 AM
(meanF S.E. of three separate experiments) (Fig. 6B and
Table 1).
The effects of amino acid-related compounds on the L-
leucine transport in T24 cells were investigated by measur-
ing the [14C]L-leucine uptake in the presence of the non-
labeled amino acid-related compounds. As shown in Fig.
7A, [14C]L-leucine uptake by T24 cells was markedly
inhibited by L-dopa, 3-O-methyldopa, a-methyltyrosine,
a-methyldopa and gabapentin as well as leucine phenyl-
alanine and tyrosine. Triiodothyronine, thyroxine, and mel-
phalan also inhibited [14C]L-leucine uptake (Fig. 7B). In
contrast, carbidopa and droxidopa did not inhibit [14C]L-
leucine uptake (Fig. 7A). The inhibition of [14C]L-leucine
uptake by phenylalanine, tyrosine, L-dopa, 3-O-methyldopa,
a-methyltyrosine, a-methyldopa, gabapentin, triiodothyro-
nine, thyroxine and melphalan was in a competitive manner
(data not shown). The Ki values for these compounds are
provided in Table 1.
3.4. The properties of [14C]L-leucine efflux from T24 cells
To examine the properties of [14C]L-leucine efflux from
T24 cells, T24 cells were loaded with [14C]L-leucine by
Fig. 7. Inhibition of [14C]L-leucine uptake by amino acid analogues in T24
cells. (A) The [14C]L-leucine uptake (20 AM) was measured for 1 min in the
presence of 2 mM nonradiolabeled L-leucine (Leu), L-tyrosine (Tyr), L-dopa
(Dopa), 3-O-methyldopa (3-O-MeDopa), a-methyltyrosine (a-MeTyr), a-
methyldopa (a-MeDopa), carbidopa, droxidopa or gabapentin. The values
are expressed as a percentage of control [14C]L-leucine uptake in the
absence of inhibitors ( ). (B) The [14C]L-leucine uptake (1 AM) was
measured for 1 min in the presence of 100 AM nonradiolabeled L-leucine
(Leu), triiodothyronine (T3), thyroxine (T4) and melphalan. The values are
expressed as a percentage of control [14C]L-leucine uptake measured in the
absence of inhibitors ( ). Table 1
Ki values of unlabeled amino acid-related compounds on the uptake of
[14C]L-leucine into T24 cells
Compounds Ki (AM)a
Phenylalanine 55.2F 1.90
Tyrosine 60.4F 3.74
Dopa 138F 6.90
3-O-Methyldopa 96.5F 7.80
a-Methyltyrosine 153F 23.5
a-Methyldopa 216F 18.7
Gabapentin 191F16.7
Triiodothyronine 7.30F 0.80
Thyroxine 162F 19.7
Melphalan 75.3F 6.84
BCH 156F 7.90
a Ki values were determined as described in Materials and methods.
The table was constructed based on three separate experiments.
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being incubated for 10 min in the uptake solution containing
1 AM [14C]L-leucine. The efflux of loaded radioactivity was
measured in the presence or absence of nonlabeled L-leucine
in the extracellular medium. Nearly 60% of the loaded
radioactivity appeared in the extracellular medium in 1 min
in the presence of extracellular 0.1 or 1 mM L-leucine (Fig.
8A). The extracellularly applied L-leucine induced the efflux
of preloaded [14C]L-leucine in a concentration-dependent
manner (Fig. 8B). The Km value of extracellularly applied
L-leucine to induce the preloaded [14C]L-leucine efflux was
103.8F 8 AM. The efflux of [14C]L-leucine was not depend-
ent on the extracellular Na + (data not shown).
3.5. [14C]L-leucine efflux induced by amino acid-related
compounds
The amino acid-related compounds that inhibited [14C]L-
leucine uptake in T24 cells were investigated to examine
Fig. 8. [14C]L-Leucine efflux from T24 cells. (A) Time course of [14C]L-
leucine efflux from T24 cells preloaded with [14C]L-leucine. The efflux was
measured in the presence (0.1 mM L-Leu; 1 mM L-Leu) or absence (0 mM
L-Leu) of L-leucine in the extracellular medium. The values are expressed
as a percentage of the total radioactivity loaded to the T24 cells (see
Materials and methods). (B) The dependence of [14C]L-leucine efflux on the
concentration of extracellular L-leucine. T24 cells were preloaded with
[14C]L-leucine by being incubated in the uptake solution containing 1 AM
[14C]L-leucine for 10 min. The efflux of loaded [14C]L-leucine induced by
extracellularly applied L-leucine was measured for 1 min and plotted
against extracellular L-leucine concentration. Inset: Eadie–Hofstee plot of
the [14C]L-leucine efflux used to determine kinetic parameters. The L-
leucine efflux was saturable and fit to a Michaelis–Menten curve. The Km
and Vmax values were 103.8F 8.0 AM and 54.2F 0.4% radioactivity,
respectively.
Fig. 9. Efflux of [14C]L-leucine by amino acid-related compounds. (A)
Efflux of preloaded [14C]L-leucine induced by amino acid-related
compounds. The efflux of preloaded [14C]L-leucine from the T24 cells
was measured for 1 min in the presence of 100 AM L-leucine (Leu),
L-phenylalanine (Phe), L-tyrosine (Tyr), BCH, L-dopa (Dopa), 3-O-
methyldopa (3-O-MeDopa), a-methyltyrosine (a-Metyr), a-methyldopa
(a-MeDopa), carbidopa, droxidopa, gabapentin, triiodothyronine (T3),
thyroxine (T4), melphalan or proline (Pro) in the medium and compared
with that measured in the absence of these compounds ( ). (B) The
concentration dependence of the effect of extracellular triiodothyronine,
thyroxine and melphalan to induce [14C]L-leucine efflux. The efflux of
preloaded [14C]L-leucine from the T24 cells was measured for 1 min in the
presence of varied concentration of triiodothyronine (T3, filled circle),
thyroxine (T4, filled square) and melphalan (filled triangle) in the medium.
*P < 0.05 vs. control (the efflux measured in the absence of triiodothyr-
onine, thyroxine or melphalan), * * *P< 0.001 vs. control (the efflux
measured in the absence of triiodothyronine, thyroxine or melphalan).
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whether they induce efflux of preloaded [14C]L-leucine
when applied extracellularly. As shown in Fig. 9A, extrac-
ellularly applied L-leucine, L-phenylalanine, L-tyrosine,
BCH, L-dopa, 3-O-methyldopa, a-methyltyrosine, a-meth-
yldopa and gabapentin induced high levels of efflux of
preloaded [14C]L-leucine. Triiodothyronine, thyroxine and
melphalan induced lower but significant efflux of the
preloaded [14C]L-leucine (Fig. 9A). The efflux of preloaded
[14C]L-leucine induced by triiodothyronine, thyroxine and
melphalan was shown to be dependent on the concentration
of extracellularly applied triiodothyronine, thyroxine and
melphalan (Fig. 9B). Significant efflux was not induced by
carbidopa and droxidopa (Fig. 9A).
4. Discussion
In the present study, we investigated the expression of
system L transporters and the properties of L-leucine trans-
port in T24 human bladder carcinoma cells. We demonstra-
ted by Northern blot and real-time quantitative PCR that
T24 cells express LAT1, an isoform of system L transporter,
at high levels together with its associating protein, 4F2hc.
T24 cells do not express the other system L isoform, LAT2
(Fig. 1). In the Western blot analysis which we performed in
the previous study on the membrane fraction prepared from
T24 cells, we detected proteins for LAT1 and 4F2hc con-
nected with each other via a disulfide bond [10]. In the
present study, we performed an immunofluorescence micro-
scopic analysis on T24 cells and showed that LAT1 protein
is present in the plasma membrane of T24 cells with 4F2hc
protein (Fig. 2). Therefore, it is concluded that T24 cells
express LAT1 but not LAT2 in the plasma membrane as a
partner of 4F2hc.
The [14C]L-leucine uptake measured in T24 cells was
Na + -independent and almost completely inhibited by the
system L selective inhibitor BCH [1,34] (Fig. 3A and B).
This suggests that the majority of L-leucine uptake by T24
cells is mediated by system L. Because, as already men-
tioned, T24 cells express LAT1, one of the two system L
transporters, LAT1 is proposed to be responsible for the L-
leucine uptake by T24 cells. The [14C]L-leucine uptake by
T24 cells is saturable and followed Michaelis–Menten
kinetics (Fig. 4B). The Km value for the [
14C]L-leucine
uptake was f 100 AM, relatively higher than those of
human LAT1 and rat LAT1 expressed in Xenopus oocytes
(f 20 AM), which may be due to different cell systems and
conditions used [9,10]. The profiles of inhibition of [14C]L-
leucine uptake by L- and D-amino acids in T24 cells were
basically identical to those determined for human LAT1 and
rat LAT1 expressed in Xenopus oocytes, except that [14C]L-
leucine uptake was more strongly inhibited by L-cysteine, L-
threonine, D-isoleucine, D-tyrosine and D-histidine in T24
cells [9,10] (Fig. 5A and B).
BCH is an amino acid-related compound which has been
used as a selective inhibitor of system L [1,34]. It was,
however, shown that the transport mediated by a Na + -
dependent neutral and basic amino acid transporter ATB0, +
with the characteristics of system B0, + is also inhibited by
BCH [35]. In the Na + -free condition, however, it is still
correct that BCH selectively inhibits system L transport.
[14C]L-leucine uptake by T24 cells was inhibited by BCH in
a concentration-dependent fashion (Fig. 6A). The inhibition
was shown to be competitive with a Ki value of f 150 AM
(Fig. 6B).
Consistent with the properties of rat LAT1 expressed in
Xenopus oocytes, [14C]L-leucine uptake by T24 cells was
strongly inhibited by L-dopa, 3-O-methyldopa, a-methyltyr-
osine, a-methyldopa and gabapentin, whereas carbidopa
and droxidopa did not exert remarkable inhibitory effects
on the [14C]L-leucine uptake (Fig. 7A). The Ki values for
these compounds were comparable with those determined in
rat LAT1 expressed in Xenopus oocytes (Table 1 and Ref.
[11]). As shown in Fig. 7B, [14C]L-leucine uptake by T24
cells was inhibited by triiodothyronine, thyroxine and mel-
phalan, consistent with human LAT1 and rat LAT1
expressed in Xenopus oocytes [10,11]. As already shown
for rat LAT1 expressed in Xenopus oocytes, triiodothyronine
exhibited the lowest Ki value (f 7 AM for T24 cells (Table
1); f 6 AM for rat LAT1 expressed in Xenopus oocytes
Ref. [11]) among the compounds tested.
The profiles of inhibition of [14C]L-leucine uptake by
amino acids and amino acid-related compounds in T24 cells
are, thus, in principle, comparable to those for human LAT1
and rat LAT1 expressed in Xenopus oocytes [9–11]. As
already discussed, the examinations on the expression of
messages and proteins have revealed that LAT1 is the
predominant system L transporter in T24 cells. Taken
together, it is concluded that the majority of [14C]L-leucine
uptake is mediated by LAT1 in T24 cells. This indicates that
the T24 cell system is an excellent tool to screen the
compounds which interact with LAT1 by measuring the
effects on the [14C]L-leucine uptake.
It was already shown that LAT1 mediates the exchange
of amino acids [9–11]. In rat LAT1 expressed in Xenopus
oocytes, we previously showed that the measurement of the
efflux of preloaded radiolabeled substrates can be a means
to evaluate whether the compounds that inhibit LAT1-
mediated transport are transportable substrates or nontrans-
portable blockers [11]. This strategy is, in particular, useful
for the compounds whose radiolabeled forms are not avail-
able [33,36,37]. In the present study, we performed efflux
measurements in T24 cells. T24 cells were preloaded with
[14C]L-leucine by being incubated for 10 min in the uptake
solution containing 1 AM [14C]L-leucine. As shown in Fig.
8A, by responding to the extracellularly applied 100 AM L-
leucine, f 60% of preloaded radioactivity was effluxed
from T24 cells to the medium in 1 min. The rate of the
efflux of radioactivity was dependent on the concentration
of the extracellularly applied L-leucine with the Km value
of f 100 AM (Fig. 8B), comparable with that of L-leucine
uptake by T24 cells (f 100 AM). This is consistent with the
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concept of obligatory exchange for the transport mediated
by LAT1 [9–11]. We thus concluded that the efflux meas-
urement procedure can also be applicable to T24 cells.
By performing the efflux measurements in T24 cells,
we examined whether the amino acid-related compounds
induce the efflux of preloaded [14C]L-leucine. Consistent
with the efflux measurements performed on rat LAT1
expressed in Xenopus oocytes, L-dopa, 3-O-methyldopa,
a-methyltyrosine, a-methyldopa and gabapentin induced
high level of efflux of preloaded [14C]L-leucine (Fig. 9A).
In addition, we examined BCH in the present study to
show that BCH also induces the efflux of preloaded
[14C]L-leucine (Fig. 9A). These compounds are supposed
to be transported by LAT1 in T24 cells. In rat LAT1
expressed in Xenopus oocytes, triiodothyronine, thyroxine
and melphalan did not induce detectable levels of efflux of
preloaded [14C]L-phenylalanine although they exhibited
inhibitory effects on [14C]L-phenylalanine uptake, consis-
tent with the low transport rates for [125I]triiodothyronine
and [125I]thyroxine via rat LAT1 expressed in Xenopus
oocytes [11]. In the present study, however, the significant
efflux of preloaded [14C]L-leucine was detected by the
application of triiodothyronine, thyroxine and melphalan to
the T24 cells, which was dependent on the concentration
of extracellularly applied triiodothyronine, thyroxine and
melphalan (Fig. 9A and B). This indicates that the efflux
measurements in T24 cells is more sensitive than those in
Xenopus oocytes.
For thyroid hormones triiodothyronine and thyroxine, it
was already shown that they are transported by LAT1
although the transport rate is low in spite of their high
affinity to LAT1. However, it was not determined whether
melphalan is in fact transported by LAT1 or not. In this
study, we showed that melphalan induces significant efflux
of preloaded [14C]L-leucine from T24 cells (Fig. 9A and
B). This is the first to demonstrate that melphalan is
transported by LAT1. Greig et al.[38] reported that mel-
phalan is transported across the blood–brain barrier via
system L, which is presumably mediated by LAT1
expressed in the blood–brain barrier. Melphalan was, in
addition, shown to be transported by system L in in vivo
preparation [39]. The level of system L activity in tumor
cells was reported to be correlated with melphalan sensi-
tivity [40,41]. Because LAT1 is up-regulated in tumor
cells, LAT1 is proposed to be at least one of the major
routes through which melphalan permeates the plasma
membrane to enter the tumor cells.
In the present study, we have characterized the [14C]L-
leucine uptake by T24 cells and shown that it is mediated by
LAT1 a isoform of system L transporter. We propose,
therefore, that the T24 cell system is an excellent tool to
examine the interaction of chemical compounds with LAT1.
Because LAT1 is up-regulated in tumor cells to support their
continuous growth, the inhibition of LAT1 would be a new
rationale to suppress tumor cell growth. T24 cell would be
useful to screen the chemical compounds for the inhibitors
of LAT1. In addition, we showed, in the present study, that
the efflux of preloaded [14C]L-leucine from T24 cells is a
sensitive means to evaluate whether the compounds which
inhibited LAT1-mediated transport is in fact transported by
LAT1 or not. The T24 cell system is, therefore, also useful
to develop drugs with efficient permeation through the
blood–brain barrier utilizing LAT1 as a permeation path.
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